Degradation of radiolabelled arginine vasopressin (125I-AVP) by the human placenta perfused in vitro.
The capacity of the human placenta to degrade 125I-labelled arginine vasopressin (125I-AVP) was studied in vitro using a dual circuit perfused lobule preparation. Seven placentas were perfused with the perfusate on the maternal side of the lobule containing 125I-AVP at the upper limit of the physiological range. On average, over a 30-min period, 48% of the 125I-AVP appeared to have been metabolized. With one exception, a patient whose labour was augmented with intravenous oxytocin, no 125I-AVP apparently crossed the placental lobule to the fetal circulation. These data indicate that the human placenta has a considerable capacity to degrade AVP.
Landon
M J
MJ
Section of Perinatal and Child Health, Clinical Research Centre, Harrow, Middlesex.
Copas
D K
DK
Shiells
E A
EA
Davison
J M
JM
D000328:Adult; D001127:Arginine Vasopressin / Q000378:metabolism*; D001775:Blood Circulation; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D007457:Iodine Radioisotopes / Q000378:metabolism; D008431:Maternal-Fetal Exchange; D010920:Placenta / Q000378:metabolism* / Q000502:physiology; D011247:Pregnancy
D007457:Iodine Radioisotopes; D001127:Arginine Vasopressin